Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis

Stefano Barco1*, Seyed Hamidreza Mahmoudpour1,2, Benjamin Planquette3,4, Olivier Sanchez3,4, Stavros V. Konstantinides1,5, and Guy Meyer3,4

1Center for Thrombosis and Haemostasis (CTH), University Medical Centre of the Johannes Gutenberg University, Langenbeckstraße 1, 55131 Mainz, Germany; 2Department of Biometry and Bioinformatics, Institute for Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Centre of the Johannes Gutenberg University, Obere Zahlbacher Straße 69, 55131 Mainz, Germany; 3,4CRIN INNOVTE, Hôpital Nord, CHU Saint Etiene, Avenue Albert Raimond, 42270 Saint Priest en Jarez (Saint Etienne), France; 5Service de Pneumologie et de Soins Intensifs, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S 1140, 20 rue Leblanc, 75015 Paris, France; and 6Department of Cardiology, Democritus University of Thrace, University General Hospital, 68100 Alexandroupolis, Greece

Received 22 October 2018; revised 14 November 2018; editorial decision 30 November 2018; accepted 3 December 2018; online publish-ahead-of-print 27 December 2018

See page 911 for the editorial comment on this article (doi: 10.1093/eurheartj/ehz018)

Aims
Patients with acute pulmonary embolism (PE) classified as low risk by the Pulmonary Embolism Severity Index (PESI), its simplified version (sPESI), or the Hestia criteria may be considered for early discharge. We investigated whether the presence of right ventricular (RV) dysfunction may aggravate the early prognosis of these patients.

Methods and results
We did a systematic review and meta-analysis of studies including low-risk patients with acute PE to investigate the prognostic value of RV dysfunction. Diagnosis of RV dysfunction was based on echocardiography or computed tomography pulmonary angiography. In addition, we investigated the prognostic value of elevated troponin or natriuretic peptide levels. The primary outcome was all-cause mortality at 30 days or during hospitalization. We included 22 studies (N=3295 low-risk patients) in the systematic review: 21 were selected for quantitative analysis. Early all-cause mortality rates in patients with vs. without RV dysfunction on imaging were 1.8% [95% confidence interval (CI) 0.9–3.5%] vs. 0.2% (95% CI 0.03–1.7%), respectively, [odds ratio (OR) 4.19, 95% CI 1.39–12.58]. For troponins, rates were 3.8% (95% CI 2.1–6.8%) vs. 0.5% (95% CI 0.2–1.3%), (OR 6.25, 95% CI 1.95–20.05). For natriuretic peptides, only data on early PE-related mortality were available: rates were 1.7% (95% CI 0.4–6.9%) vs. 0.4% (95% CI 0.1–1.1%), (OR 3.71, 95% CI 0.81–17.02).

Conclusions
In low-risk patients with acute PE, the presence of RV dysfunction on admission was associated with early mortality. Our results may have implications for the management of patients who appear at low risk based on clinical criteria alone, but present with RV dysfunction as indicated by imaging findings or laboratory markers.

Keywords
Pulmonary embolism • Home treatment • Risk stratification • Right ventricular dysfunction • Mortality • Anticoagulation

* Corresponding author. Tel: +49 6131 17 8251, Fax: +49 6131 17 8461, Email: s.barco@uni-mainz.de

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Acute pulmonary embolism (PE) contributes to the global burden of cardiovascular disease in terms of morbidity, mortality, and financial impact on healthcare systems. Current management strategies are tailored to the patient’s risk of early death or other serious early complications. In the 2014 European Society of Cardiology (ESC) Guidelines, risk stratification of patients with acute PE is based on three sets of criteria: (i) haemodynamic status and clinical characteristics at baseline, (ii) findings of right ventricular (RV) dysfunction on imaging, notably echocardiography or computed tomography pulmonary angiography (CTPA), and (iii) elevation of cardiac biomarkers, particularly cardiac troponins and natriuretic peptides, indicating myocardial injury and (right) heart failure, respectively. A reliable risk classification of PE has immediate clinical implications, notably with regard to the decision on whether to hospitalize the patient or discharge him/her to ambulatory treatment. Home treatment may improve satisfaction with treatment and more generally the quality of life of patients with acute PE; in addition, it may help to reduce costs as well as potential health risks related to unnecessary hospitalization. This is particularly important in view of the fact that, in many countries, patients with acute PE are still hospitalized for several days. Cohort studies and randomized controlled trials, which investigated the efficacy and safety of ambulatory PE treatment in the vitamin K antagonist (VKA) era, used mainly clinical severity scores for patient selection. These include the Pulmonary Embolism Severity Index (PESI), its simplified version (sPESI), and the Hestia criteria. In the years to come, non-VKA oral anticoagulants may facilitate early discharge and outpatient treatment for selected patients with acute PE. Consequently, the 2014 ESC Guidelines on the management of acute PE proposed an algorithm, in which a low clinical risk based on the PESI (or sPESI) alone could justify early discharge without the need for further testing. However, caution is warranted and maximum safety is imperative when judging a patient to be at sufficiently low risk to be released from medical attention. In this context, accumulating reports appear to suggest that standardized clinical severity scores alone might be insufficient to exclude subclinical RV dysfunction and thus an intermediate risk of early complications. Therefore, we conducted the present systematic review and study-level meta-analysis to determine the prognostic relevance of RV dysfunction resulting from RV pressure overload, detected on echocardiography or CTPA, or of elevated cardiac biomarkers, in patients with acute PE classified into the low-risk category according to current clinical severity scores.

Methods

Literature search and study selection

We conducted a systematic search of the literature for publications in PubMed or Web of Science between October 2008 and May 2018, that is after the derivation and validation of the PESI and the publication of the 2008 ESC guidelines on acute PE, in which an advanced concept of risk stratification was first introduced. We performed an additional manual search of potentially eligible studies within references of the included studies, international guidelines, relevant (systematic) reviews, and derivation/validation studies of prognostic scores. The literature search strategy is available as Supplementary material online.

Search results were screened independently by two reviewers for the relevance of titles/abstracts and full-texts of the studies fulfilling the inclusion criteria. Potential disagreements were solved by a third reviewer. The authors of publications with missing data were contacted at least twice within a 2-week period. The present work was performed in accordance with the PRISMA and MOOSE guidelines. We registered the study protocol in PROSPERO (CRD42018103926).

Eligibility criteria

Studies were considered eligible if they fulfilled all the following criteria:

i. They included normotensive patients (or provided subgroup data for this category of patients) not selected based on the presence/absence of RV dysfunction, with an objectively confirmed diagnosis of acute PE, and categorized as being at low risk according to either the (s)PESI (PESI Classes I or II, PESI < 86 points, or sPESI = 0) or Hestia (all criteria absent);

ii. The study evaluated the prognostic role of RV dysfunction on admission, here primarily defined as the presence of signs of RV pressure overload on imaging tests (echocardiography or CTPA) among low-risk patients, or, alternatively, as myocardial injury based on elevated cardiac troponins or natriuretic peptides;

iii. At least one of the outcomes of interest was assessed during short-term (either at 30 days or, if not available, in-hospital) or 90-day follow-up.

The description of the items that are part of the clinical scores are summarized in the Supplementary material online. Two authors independently assessed the quality of studies focusing on clinical outcomes in accordance with the Newcastle–Ottawa Scale for cohort studies.

Right ventricular dysfunction and elevated cardiac biomarkers

Visualization of RV dysfunction (due to pressure overload) at presentation was based on echocardiography or CTPA. Since the definition of the parameters of RV dysfunction, and the cut-off values that were used, varied over time, we included studies requiring at least one of the following criteria: dilatation of the right ventricle (e.g. diastolic diameter ≥30 mm in the parasternal short-axis view) on echocardiography or an elevated RV/left ventricular end-diastolic diameter ratio (cut-off of 0.9 or 1.0) on echocardiography, or CTPA; hypokinesia of the RV free wall or abnormal motion of the interventricular septum on echocardiography; tricuspid valve regurgitation velocity (cut-off 2.7 or 2.8 m/s) on echocardiography. We further defined myocardial injury and (right) heart failure based on elevated circulating levels of cardiac troponins [troponin I (TnI) or T (TnT), by standard or high-sensitivity (hs) assays] and natriuretic peptides [B-type natriuretic peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP)], respectively. Since current ESC guidelines do not recommend specific assays or cut-offs, we based our classification on the cut-offs reported in the selected studies.

Study outcomes

We defined early all-cause mortality, i.e. death during the hospital stay or within the first 30 days following diagnosis of acute PE, as the primary outcome of our meta-analysis. The secondary outcomes were (i) early PE-related adverse outcome, defined as (PE-related) mortality, haemodynamic collapse (with need for cardiopulmonary resuscitation, mechanical ventilation, or catecholamine administration), or recurrent venous thromboembolism (VTE); (ii) early PE-related mortality; and (iii) long-term all-cause mortality.
Statistical analysis
We calculated pooled odds ratios (ORs), weighed rates, and absolute risk differences between groups of patients with vs. without RV dysfunction applying a random-effect model [95% confidence interval (CI)]. An exact binomial approach was preferred since the proportions were expected to be close to the low boundary. We assessed (statistical) heterogeneity of exposure effects by calculating the $I^2$ statistic, which summarizes the amount of variance among studies beyond chance. Heterogeneity was defined as low ($I^2 < 25\%$), moderate ($I^2 = 25–75\%$), or high ($I^2 > 75\%$). The presence of publication bias was evaluated by visually inspecting funnel plots if >10 studies were analysed. We performed predefined subgroup analyses investigating the prognostic value of different cut-offs and tests, the rate of complications in inpatient vs. outpatient, and differences between studies grouped by study design (prospective or management studies vs. post hoc analyses). RevMan 5.3 (Cochrane Collaboration) and R 3.4.3 (mada, metafor) served for data analysis.

Results
Systematic review of the literature
The literature search identified 1814 records in *PubMed* and 1952 in *Web of Science*, leaving 2415 records after duplicate removing. The process of study selection is summarized in Figure 1. We identified three additional studies not retrieved by our initial search. Eventually, we included 22 studies in the systematic review for a total of 7536 patients diagnosed with acute PE (Table 1). Of these patients, 3295 were classified as being at low risk according to the PESI [1516/3265 (46%)], the sPESI [932/2639 (35%)], or the Hestia criteria [847/1632 (52%)]. Additional information on the individual studies included in the systematic review of the literature is shown in the Supplementary material online, *Tables S1* and *S2*. The study outcomes and quality assessment are summarized in the Supplementary material online, *Tables S3* and *S4*.

Twenty cohort studies adopted PESI or sPESI for risk stratification of the patients, while two adopted the Hestia criteria. One study did not provide complete information on outcomes, and it was therefore excluded from the meta-analysis. Eventually, a total of 21 studies were selected for the quantitative analysis.

Early all-cause mortality
Among patients classified as being at low risk by the PESI, sPESI, or the Hestia criteria, 34% (95% CI 30–39%) tested positive for cardiac troponin I or T (n = 13 studies, n = 1458 patients). Of these, seven studies (n = 1597 patients) provided data on early all-cause mortality. As shown in Table 2 and Figure 2, early all-cause mortality rates of this ‘low-risk’ population were 1.8% (95% CI 0.9–3.5%) and 0.2% (0.03–1.7%) in the presence and absence of RV dysfunction, respectively, corresponding to an OR of 4.19 (95% CI 1.39–12.58; $I^2$ 0%; Figure 3).

Among low-risk PE patients based on the PESI or sPESI, 26% (95% CI 17–39%) tested positive for cardiac troponin I or T (n = 13 studies, n = 1458 patients). Of these, eleven studies (n = 1176 patients) provided data on early all-cause mortality. Early all-cause mortality rates were 3.8% (95% CI 2.1–6.8%) and 0.5% (95% CI 0.2–1.3%) in patients with and without elevated troponin levels, respectively.
### Table 1  Characteristics of the studies included after systematic review of the literature

| Study                  | N    | Low risk, n (%) | Men, n (%) | Age (standard deviation or interquartile range) | Early discharge, n (%) | Exposure                                   | Study population                                      |
|------------------------|------|-----------------|------------|-----------------------------------------------|------------------------|-------------------------------------------|-------------------------------------------------------|
| **Erol et al.** 38      | 110  | 34 (31), sPESI  | 14 (42)    | 47 (range 21–79)                              | 0                      | RV dysfunction (echo), TnI, NT-proBNP    | Pneumology Department                                 |
| Singanayagam et al. 20  | 585  | 288 (49), PESI  | 251 (43)*  | 55% >65 years*                                | —                      | RV dysfunction (CTPA)                    | Without known thrombophilia, haematological malignancy, or ongoing anticoagulation (Emergency Room) |
| **Palmieri et al.** 39  | 89   | 27 (30), PESI  | 6 (22)     | 24 (18) PESI I, 57 (21) PESI II               | —                      | RV dysfunction (echo), Troponin          | Acute central without renal failure, recent acute coronary syndrome, or haemodynamic instability on admission (Emergency Room) |
| PROTECT 27,28           | 848  | 313 (37), sPESI | 416 (49)*  | 72 (59–80)*                                   | —                      | RV dysfunction (echo and CTPA), BNP       | Without haemodynamic instability, life expectancy <3 months, pregnancy, geographic inaccessibility |
| **PREP** 21             | 529  | 329 (62), PESI | 247 (47)*  | 67 (52–77)*                                   | —                      | RV dysfunction (echo), TnI, BNP          | Patients not anticoagulated for >24 h or with cardiogenic shock at admission |
| **Côté et al.** 11      | 779  | 779 (100), sPESI| 347 (45)*  | 61 (44–72)*                                   | —                      | RV dysfunction (CTPA)                    | Patients from PREP study, PROTECT study, and consecutive patients from a single-centre prospective registry |
| **Hakemi et al.** 22    | 298  | 173 (58), PESI  | 151 (51)*  | 56 (13)*                                       | —                      | hsTnI                                     | Patients admitted for acute PE                       |
| **Lankeit et al.** 29   | 526  | 198 (37), sPESI | 266 (51)*  | 71 (55–79)*                                   | —                      | TnI                                       | Normotensive patients at presentation; PERGO, PROTECT, and Polish cohorts |
| **Lankeit et al.** 30   | 688  | 258 (38), sPESI | 326 (47)*  | 70 (54–78)*                                   | —                      | NT-proBNP                                 | Emergency Room                                        |
| **Vanni et al.** 23     | 540  | 145 (31), PESI  | 65 (45)    | 73% >65 years                                 | —                      | RV dysfunction (echo)                    | Emergency Room                                        |
| **Kartal et al.** 31    | 68   | 30 (44), sPESI  | 30 (44)*   | 60 (18)*                                       | 23 (34)                | TnI                                       | Without prior pulmonary hypertension, suboptimal imaging tests, and pregnancy (Emergency Room) |
| **Moores et al.** 24    | 567  | 191 (34), PESI  | 245 (43)*  | 74% >65 years*                                | 191 (100)              | TnI                                       | Outpatients (Emergency Room)                         |
| **Ozsu et al.** 32      | 121  | 45 (38), sPESI  | 52 (43)*   | 70 (55–76)*                                   | —                      | hsTnT, TnT                                | Emergency Room                                        |
| **Ozsu et al.** 33      | 206  | 59 (29), sPESI  | 82 (40)*   | 71 (58–80)*                                   | 31 (15)                | TnT                                       | Emergency Room                                        |
| **SWIVTER** 14          | 369  | 106 (29), sPESI | 66 (62)    | 72 (13)                                       | 49 (46)                | TnL, hsTnT, TnT                          | With available troponin measurement                   |
| **Polo Friz et al.** 35 | 106  | 34 (32), sPESI  | 35 (33)*   | 74 (14)*                                       | —                      | hsTnT                                     | Emergency Room                                        |
| **Weekes et al.** 36    | 123  | 53 (43), sPESI  | 63 (51)*   | 59 (43–69)*                                   | —                      | RV dysfunction (CTPA), TnI, BNP          | Hospitalized because of acute PE                     |
| **Choi et al.** 25      | 657  | 363 (64), PESI  | 295 (45)   | 68                                            | —                      | RV dysfunction (echo), TnI, NT-proBNP    | Selected for anticoagulant treatment at home          |
| **HESTIA** 38           | 530  | 297 (56), Hestia| 159 (58)   | 55 (16)                                       | 275 (100)              | RV dysfunction (echo)                    | Selected for anticoagulant treatment at home, life expectancy >3 months |
| **VESTA** 37            | 1102 | 550 (50), Hestia| 297 (54)   | 54 (15)                                       | 275 (100)              | NT-proBNP                                 | Selected for anticoagulant treatment at home, life expectancy >3 months |
| **Systematic review only** |      |                 |            |                                               |                        |                                           |                                                       |
| Singanayagam et al. 16  | 411  | 214 (52), PESI  | 177 (43)*  | 55% >65 years*                                | —                      | TnI                                       | First PE; without thrombophilia, haematological malignancy, or ongoing anticoagulation (Emergency Room) |

BNP, B-type natriuretic peptide; CTPA, computed tomography pulmonary angiography; hsTnI, (high sensitivity) troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PE, pulmonary embolism; RV, right ventricular; (s)PESI, (simplified) pulmonary embolism severity index; TnI, troponin I.

*Baseline characteristics referring to the overall study population.
corresponding to an OR of 6.25 (95% CI 1.95–20.05; I² 0%). The corresponding proportions of low-risk patients testing positive for BNP and NT-proBNP were 30% (95% CI 26–33%) and 23% (95% CI 12–40%) of tested (n = 7 studies, n = 1663 patients). No data on all-cause mortality were reported in these latter studies.

Table 2  Rates of short-term adverse events in low-risk patients with or without imaging and laboratory indicators of right ventricular dysfunction or myocardial injury

| RV dysfunction (exposure) | Study population (n studies) | With RV dysfunction, % (95% CI) | Without RV dysfunction, % (95% CI) |
|---------------------------|-------------------------------|---------------------------------|------------------------------------|
| Early all-cause mortality | RV pressure overload (echo/CTPA) | 1597 (7) | 1.8 (0.9–3.5) | 0.2 (0.03–1.7) |
|                           | Troponin                      | 1176 (11) | 3.8 (2.1–6.8) | 0.5 (0.2–1.3) |
|                           | BNP/NT-proBNP                 | —        | —               | —               |
| Early PE-related adverse outcome | RV pressure overload (echo/CTPA) | 1488 (6) | 3.7 (0.9–14.4) | 0.7 (0.06–6.4) |
|                           | Troponin                      | 1137 (8) | 10.2 (7.2–14.3) | 0.6 (0.1–5.6) |
|                           | BNP/NT-proBNP                 | 1405 (6) | 5.4 (1.8–14.6) | 1.3 (0.6–2.6) |

The PE-related adverse outcome includes PE-related mortality, haemodynamic collapse, and/or recurrent venous thromboembolism. BNP, B-type natriuretic peptide; CTPA, computed tomography pulmonary angiography; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PE, pulmonary embolism; RV, right ventricular.

Figure 2 (A) Early mortality and early pulmonary embolism-related adverse outcome rates in patients with vs. without right ventricular dysfunction. An early pulmonary embolism-related adverse outcome (B) was defined as early death, haemodynamic collapse, and/or recurrent venous thromboembolism. Red dots (with corresponding confidence intervals) represent estimates in the presence of right ventricular dysfunction; blue dots, in its absence. BNP, B-type natriuretic peptide; CTPA, computed tomography pulmonary angiography; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PE, pulmonary embolism; 95% CI, 95% confidence interval.

Early pulmonary embolism-related outcome

As shown in Table 2 and Figure 2, the rates of an early adverse outcome (PE-related mortality, haemodynamic collapse, or recurrent VTE) were 3.7% (95% CI 0.9–14.4%) and 0.7% (95% CI 0.06–6.4%) in
patients with vs. without RV dysfunction on echocardiography or CTPA (n = 6 studies, n = 1488 patients), respectively, corresponding to an OR of 3.37 (95% CI 1.73–6.57; I² 0%; Figure 4).

In patients with a positive vs. negative cardiac troponin test (n = 8 studies, n = 1137 patients), the corresponding rates were 10.2% (95% CI 7.2–14.3%) vs. 0.6% (95% CI 0.1–5.6%), for an OR of 5.14 (95% CI 2.65–9.97; I² 0%). Finally, for those with BNP/NT-proBNP values above and below the cut-off used (n = 6 studies, n = 1405 patients), the rates were 5.4% (95% CI 1.8–14.6%) and 1.3% (95% CI 0.6–2.6%), respectively, resulting in an OR of 3.63 (95% CI 1.69–7.80; I² 0%).

We calculated separately the pooled rates of early PE-related mortality. These rates were 1.3% (95% CI 0.5–3.1%) vs. 0.02% (95% CI 0.01–21.4%) in patients with and without RV dysfunction on imaging (n = 8 studies, n = 1699 patients), respectively; 1.3% (95% CI 0.3–5.4%) vs. 0.4% (95% CI 0.1–2.0%) in those with and without elevated troponin levels (n = 10 studies, n = 1199 patients); and 1.7% (95% CI 0.4–6.9%) vs. 0.4% (95% CI 0.1–1.1%) in patients with vs. without elevated BNP or NT-proBNP levels (n = 5 studies, n = 1092 patients). Of note, pooled ORs for RV dysfunction on imaging (OR 2.95, 95% CI 1.80–4.65; I² 0%), elevated troponin (OR 1.71, 95% CI 0.50–5.86; I² 0%), and elevated BNP/NT-proBNP (OR 3.71, 95% CI 0.81–17.02; I² 0%) were based on only four, three, and three studies, respectively, since the other studies recorded no events.

We did not identify publication bias for all-cause mortality, whereas this cannot be excluded for the PE-related adverse outcome (Supplementary material online, Figure S1).

We found no differences in the additive prognostic value of RV dysfunction on imaging vs. that of laboratory biomarkers (P-values for subgroup differences reported in Figures 2 and 3). This was also the case if only studies comparing multiple markers within the same study population were analysed (data not shown). The results after exclusion of the two Hestia studies are provided in the Supplementary material online, Table S5 and Figures S2–S3.

Low-risk patients classified using standardized troponin cut-off levels or high sensitivity assays had a mortality rate similar to that of patients classified by different cut-off levels and assays [absolute risk difference -1.0% (95% CI -3.3% to +0.3%)]. The absolute risk
difference of mortality rates for NT-proBNP (cut-off 600 pg/mL) vs. BNP (cut-off 100 pg/mL) was -0.3% (95% CI -1.6% to +1.2%).

**Discussion**

The results of the present systematic review of the literature and meta-analysis indicate that RV dysfunction, primarily defined by RV pressure overload assessed on imaging tests, may have a significant impact on the early prognosis of patients classified as being at low risk based on the PESI, sPESI, or the Hestia criteria. Similar findings were obtained when the elevation of laboratory cardiac biomarkers, notably cardiac troponin or natriuretic peptides, served as a parameter of myocardial injury and (subclinical) RV dysfunction, respectively. Our results may have implications for the acute-phase management of patients who appear to be at a low risk of early death or severe complications based on clinical criteria alone. These findings also support the concept that optimal risk stratification of acute PE should include the assessment of RV status on admission.

The spectrum of PE severity largely varies and early mortality rates can range from <1% among stable patients to over 50% in the presence of haemodynamic instability. Consequently, the management of acute PE is tailored to the patient’s early risk and may include early discharge and home treatment for low-risk patients. Risk assessment models are practical and helpful for clinicians, permitting a standardized categorization of patients with acute PE into risk classes. In particular, the PESI and sPESI have been extensively validated for the identification of low-risk PE. In a randomized trial, 344 patients with acute PE and a PESI low-risk risk class of I–II were assigned to outpatient or inpatient treatment; all patients received subcutaneous enoxaparin followed by oral VKA anticoagulation. Based on these and other findings, the 2014 guidelines of the ESC proposed that patients with a low PESI or a negative sPESI be considered for home treatment.1

![Figure 4](image_url)

**Figure 4** Prognostic value of imaging and laboratory indicators of right ventricular dysfunction or myocardial injury for early pulmonary embolism-related adverse outcome in low-risk patients. The outcome includes mortality, haemodynamic collapse, and/or recurrent venous thromboembolism. BNP, B-type natriuretic peptide; CTPA, computed tomography pulmonary angiography; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricular; 95% CI, 95% confidence interval.
However, the use of clinical scores does not directly take into account the functional status of the right ventricle, which has repeatedly been shown to be a key determinant of PE prognosis. Consequently, it cannot be excluded that patients initially classified into the low-risk category, based on the parameters and cut-off values of a formal clinical severity score calculated on admission, may deteriorate few hours later due to the decompensation of previously unnoticed RV dysfunction.

The results of the present meta-analysis indicate that low-risk patients are at higher risk of early mortality if RV dysfunction is present. Due to the low absolute rate of events in this population, this question could not be adequately addressed by single studies. Of note, the early death risk of ‘low-risk’ patients with RV dysfunction appears similar to that previously reported for intermediate-risk PE. The mortality rates yielded by our meta-analysis are clearly higher than those reported for low-risk PE patients in studies that validated the PESI or sPESI, and raise doubts on whether such patients could be sent home safely. The paucity of data in the literature regarding event rates after early discharge and home treatment (as opposed to standard in-hospital management), or of data reported in prospective management trials (vs. post hoc analyses) did not allow us to perform additional subgroup analyses. Finally, it must be noted that the association between RV dysfunction and the outcomes was consistent across the studies, at least in terms of statistical heterogeneity ($I^2 = 0\%$). However, $I^2$ may have been underestimated due to the imprecision of single studies.

The Hestia criteria have been proposed as an alternative tool for selecting low-risk patients. Although some of these criteria are less standardized than the items included in the (s)PESI, this set of questions integrates familial, social, and broad medical factors. In light of this fact, the Hestia criteria and PESI are not directly comparable. In our meta-analysis, we could not provide pooled estimates only for the Hestia criteria due to the paucity of data in the literature. The ongoing Hospitalization or Out-treatment ManagEment of Pulmonary Embolism (HOME-PE) trial (NCT02811237) aspires to directly compare these two strategies.

**Limitations**
The present meta-analysis has a number of limitations that need to be discussed. First, several of the included studies were post hoc analyses of existing cohorts, having adopted heterogeneous criteria of RV dysfunction as well as non-prespecified cut-off values. On the other hand, it can also be argued that previous cohort studies which validated the value of the PESI, sPESI, or other criteria for defining low risk, may have included pre-selected ‘lower-risk’ populations with PE and were thus able to show such favourable results for clinical assessment alone. Second, we acknowledge that the CIs of our estimates remain wide, despite statistical significance, due to the low absolute rates of early adverse events encountered in this patient population. It is also important to mention that the present study was not designed to test if there is a single optimal biomarker or imaging parameter to quantify the early risk in patients with a low clinical score. Therefore, our results suggesting that RV pressure overload on imaging possesses prognostic value similar to the elevation of cardiac biomarkers must be considered as hypothesis-generating. An ongoing prospective management trial is investigating whether early discharge and home treatment is feasible, effective, and safe in patients who are classified into the low-risk category using the combination of clinical (modified Hestia) criteria and the absence of RV dysfunction or free-floating thrombi on an imaging test.

**Conclusion**
In conclusion, in patients with acute PE classified into the low-risk category according to clinical criteria alone, the presence of RV dysfunction was associated with an increased risk of early complications including all-cause death and PE-related serious adverse events. The estimated risk was in the lower range of that previously reported for patients with intermediate-risk PE. Right ventricular pressure overload and dysfunction on imaging appeared to possess a prognostic value comparable to the elevation of cardiac troponins or natriuretic peptides. Our results reinforce the concept of integrating the functional status of the right ventricle into the risk stratification of acute PE.

**Supplementary material**
Supplementary material is available at *European Heart Journal* online.
Acknowledgements

We would like to acknowledge the help received from Dr Cha (Kyungpook National University Hospital, Jung-Gu, Daegu, South Korea), Dr Polo Friz (Vimercate Hospital, Italy), Dr Côté (Hôpital de l’Enfant-Jésus du CHU de Québec, Université Laval, Canada), Dr Weekes (Carolinas Medical Center, Charlotte, North Carolina, USA), and Dr Singanayagam (Royal Infirmary of Edinburgh, UK), who retrieved data from the studies they co-authored.

Funding

This work was supported by the German Federal Ministry of Education and Research (BMBF-01EO1003 and 01EO1503 to S.B., S.V.K., and S.V.K.).

Conflict of interest: S.B.: congress and travel payments (Daichi Sankyo, Bayer HealthCare), lecture honoraria (Boehringer Ingelheim, Bayer HealthCare); institutional grants from Boehringer Ingelheim, Bayer HealthCare, and Pfizer-Bristol-Myers-Squibb; payment for travel accommodation/meeting expenses from Bayer; S.V.K.: consultancy and lecture honoraria from Bayer HealthCare, and Pfizer-Bristol-Myers-Squibb, Daichi Sankyo and Bayer HealthCare; institutional grants from Leo Pharma and Boehringer Ingelheim. All the other authors declared no conflict of interest.

References

1. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyzk P, Rasmussen LH, Schindler TH, Siva T, Vonk NA, Zamaro L, Zompatori M. 2013 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)/Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35:3033–3073.

2. Barco S, Woerelsch AL, Spyropoulos AC, Piovella F, Mahn CE. European Union-2B: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 2016;115:800–808.

3. Denati F, Di Micco G, Gaggi Perfranceschi M, Guissone G, Barillari G, Amirano M, Fontanella A, Lodigiani C, Guida A, Visona A, Monreal M, Di Micco P. Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Ann Med. 2015;47:546–554.

4. Konstantinides SV. Trends in pulmonary embolism outcomes: are we really making progress? J Am Coll Cardiol 2016;67:171–173.

5. Jimenez D, de Miguel-Diez J, Guijarro R, Planquette B, Di Minno MN, Celentano A. Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score. Intern Emerg Med 2008;3:131–138.

6. Singanayagam A, Chalmers JD, Scally C, Akram AR, Al-Khairalla MZ, Leitch L, Hill LE, Hill AT. Right ventricular dilatation on CT pulmonary angiogram independently predicts mortality in pulmonary embolism. Respir Med. 2010;104:1057–1062.

7. Sanchez O, Trinquet L, Planquette B, Coutraud F, Verschuren F, Caille V, Meneveau N, Pacouret G, Roy PM, Righini M, Perrier A, Bontolletti L, Parent F, Lorut C, Meyer G. Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism. Eur Respir J 2013;42:681–688.

8. Hakemi EU, Alyousef T, Dang G, Hakmej J, Doubek R. The prognostic value of undetectable highly sensitive cardiac troponin I in patients with acute pulmonary embolism. Chest 2015;147:685–694.

9. Vanni S, Nazerian P, Pepe G, Baiocchi M, Risso M, Grigioni G, Viviani G, Grigioni S. Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach. J Thromb Haemost 2011;9:1916–1923.

10. Moores L, Auesky D, Jimenez D, Diaz G, Gomez V, Marti D, Briongos S, Yusen R. Pulmonary embolism severity index and troponin testing for the selection of low-risk patients with acute symptomatic pulmonary embolism. J Thromb Haemost 2010;8:517–522.

11. Choi KJ, Cha SI, Shin KM, Lim J, Yoo SS, Lee J, Lee SY, Kim CH, Park JY, Lee WK. Prognostic implications of undetectable highly sensitive cardiac troponin T for all patients? Int J Cardiol 2015;197:162–163.

12. Donze J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, Comass J, Meyer G, Perrier A, Righini M, Auesky D. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008;100:943–948.

13. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyzk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP. ESC Guidelines Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276–2315.

14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

15. Group DP, Berlin JA, Morton SC, Olin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sie TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2008:200:283:2008–2012.

16. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (12 December 2018).

17. Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of pulmonary embolism: an update. J Am Coll Cardiol 2016;67:976–990.

18. Erol S, Batum O, Yilmaz U. Is advanced risk stratification unnecessary in patients with simplified pulmonary embolism severity index (sPESI) of D? Anatoma Molekolo 2018;71:55–59.

19. Palmieri V, Galiotta G, Rendina D, De Bonis S, Russo V, Postiglione A, Martino S, Di Minno MN, Celentano A. Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score. Intern Emerg Med 2008;3:131–138.

20. Singanayagam A, Chalmers JD, Scally C, Akram AR, Al-Khairalla MZ, Leitch L, Hill LE, Hill AT. Right ventricular dilatation on CT pulmonary angiogram independently predicts mortality in pulmonary embolism. Respir Med. 2010;104:1057–1062.
Right ventricular dysfunction in low-risk PE

31. Kartal M, Unal A, Goksu E, Yilmaz D, Gungor F. Outpatient treatment of pulmonary embolism: sPESI score and highly sensitive troponin may prove helpful. Hong Kong J Emerg Med 2017;24:132–137.

32. Ozsu S, Abdul Y, Orem A, Ozlu T. Predictive value of troponins and simplified pulmonary embolism severity index in patients with normotensive pulmonary embolism. Multidiscip Respir Med 2013;8:34.

33. Ozsu S, Bektas H, Abdul Y, Ozlu T. Value of cardiac troponin and sPESI in treatment of pulmonary thromboembolism at outpatient setting. Lung 2015;193:559–565.

34. Spirk D, Aujesky D, Hummern S, Hayoz D, Balz T, Pragogner B, Vanay M, Baumgartner I, Kucher N. Cardiac troponin testing and the simplified pulmonary embolism severity index. The SWISS Venous ThromboEmbolism Registry (SWIVTER). Thromb Res 2011;127:976–984.

35. Polo F, Molter M, Del Sorbo D, Pasciuti L, Grippa M, Villa G, Meloni DF, Primiti L, Gali A, Rognoni M, Cavaliere d’Oro L, Arpaia G, Cimminiello C. Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study. Intern Emerg Med 2015;10:431–436.

36. Weekes AJ, Johnson AK, Troha D, Thacker G, Charler-Berat J, Runyon M. Prognostic value of right ventricular dysfunction markers for serious adverse events in acute normotensive pulmonary embolism. J Emerg Med 2017;52:137–150.

37. den Exter PL, Zondag W, Klok FA, Hoving LT, de Vreede MJ, Huisman MV; Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost 2013;11:686–692.

38. Zondag W, Vingerhoets LMA, Durini MF, Doloma A, Faber LM, Hiddings BL, Hofstee HMA, Hoogerbrugge ADM, Hovens MMC, Labots G, Vlasveld T, de Vreede MJ, Koot LJM, Huisman MV. Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost 2013;11:686–692.

39. Becattini C, Agnelli G, Lankeit M, Masotti L, Pruszczyk P, Casazza F, Yami S, Nitti C, Kamphuisen P, Vedovati MC, De Natale MG, Konstantinides S. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respi J 2016;48:780–786.

40. Aujesky D, Roy PM, Verschuren F, Rigini M, Osterwalder J, Eglof M, Renaud B, Verhamme P, Stone RA, Legal C, Sanchez O, Pugh NA, N’galo A, Cormuz J, Hugli O, Beer HJ, Perrier A, Pins J, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41–48.

41. Becattini C, Agnelli G, Vedovati MC, Pruszczyk P, Casazza F, Grifoni S, Salvi A, Bianchi M, Dauma R, Konstantinides S, Lankeit M, Durant M. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J 2011;32:1657–1663.

42. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005;165:1777–1781.

43. Zhou XY, Ben SQ, Chen HL, Ni SS. The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: a meta-analysis. Respir Res 2012;13:111.

44. Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J, Duerschmied D, Baurersachs D, Empe K, Held M, Schwablmaier M, Fonseca J, Jimenez D, Becattini C, Quitzau K, Konstantinides S. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial. Thromb Haemost 2016;116:191–197.

Pulmonary haemostoma caused by percutaneous transluminal pulmonary angioplasty

Yichao Duan1, Hongling Su1, Xing Zhou2, and Yunshan Cao1,2*

1Department of Cardiology, Gansu Provincial Hospital, Lanzhou University, Lanzhou 730000, P. R. China; and 2Department of Radiology, Gansu Provincial Hospital, Lanzhou University, Lanzhou 730000, P. R. China

* Corresponding author: Tel: +86-931-8281482, Fax: +86-931-8266957, Email: yunshancao@126.com

A 77-year-old man was diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) in our hospital due to exertional dyspnoea. After evaluation of multidisciplinary team for CTEPH including cardiac surgeon, percutaneous transluminal pulmonary angioplasty (PTPA) was performed to restore pulmonary perfusion. However, during PTPA, perivascular exudation (Panel A, white arrow) was found when we dilated the stenosed right dorsal segment artery of lower lobe with balloon (Sprinter 2.0 * 20 mm) and repeated angiography revealed that the exudation disappeared. Computed tomography scan after PTPA showed pulmonary haemostoma formation (Panel B, white arrow), which has not been reported before.

This work was supported by the National Natural Science Foundation of China (81460072); CAS”Light of West China” Program; the Science Foundation of Gansu Provincial Hospital (18GSSYS-4).

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

doi:10.1093/eurheartj/ehz055
Online publish-ahead-of-print 7 February 2019